TY - JOUR
T1 - Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide
AU - Sonoyama, Takuhiro
AU - Tamura, Naohisa
AU - Miyashita, Kazutoshi
AU - Park, Kwijun
AU - Oyamada, Naofumi
AU - Taura, Daisuke
AU - Inuzuka, Megumi
AU - Fukunaga, Yasutomo
AU - Sone, Masakatsu
AU - Nakao, Kazuwa
N1 - Funding Information:
The authors thank Mr. Hirokazu Tsujimoto and Ms. Yoshie Fukuchi for technical assistance, Dr. Naoshi Nishida for expert opinions, and Mrs. Ayumi Ishida, Ms. Shiho Takada, and Ms. Aki Egami for secretarial assistance. This work was supported by the Takeda Science Foundation, the Takeda Medical Research Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Cell Science Research Foundation, the Japan Smoking Foundation, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and the Research Grant for Cardiovascular Diseases (19C-7 and 20C-3) from the Ministry of Health, Labour and Welfare.
PY - 2009/6/18
Y1 - 2009/6/18
N2 - Anti-fibrotic and organ protective effects of brain natriuretic peptide (BNP) have been reported. In this study, effects of BNP on liver fibrosis were examined in the carbon tetrachloride (CCl4)-induced liver fibrosis model using BNP-transgenic (Tg) and wild-type (WT) mice. Twice-a-week intraperitoneal injections of CCl4 for 8 weeks resulted in massive liver fibrosis, augmented transforming growth factor (TGF)-β1 and type I procollagen α1 chain (Col1a1) mRNA expression, and the hepatic stellate cell (HSC) activation in WT mice, all of which were significantly suppressed in Tg mice. These observations indicate that BNP inhibits liver fibrosis by attenuating the activation of HSCs.
AB - Anti-fibrotic and organ protective effects of brain natriuretic peptide (BNP) have been reported. In this study, effects of BNP on liver fibrosis were examined in the carbon tetrachloride (CCl4)-induced liver fibrosis model using BNP-transgenic (Tg) and wild-type (WT) mice. Twice-a-week intraperitoneal injections of CCl4 for 8 weeks resulted in massive liver fibrosis, augmented transforming growth factor (TGF)-β1 and type I procollagen α1 chain (Col1a1) mRNA expression, and the hepatic stellate cell (HSC) activation in WT mice, all of which were significantly suppressed in Tg mice. These observations indicate that BNP inhibits liver fibrosis by attenuating the activation of HSCs.
KW - Brain natriuretic peptide
KW - Carbon tetrachloride
KW - Guanylyl cyclase-A
KW - Hepatic stellate cell
KW - Liver fibrosis
UR - http://www.scopus.com/inward/record.url?scp=67349204034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349204034&partnerID=8YFLogxK
U2 - 10.1016/j.febslet.2009.05.025
DO - 10.1016/j.febslet.2009.05.025
M3 - Article
C2 - 19463821
AN - SCOPUS:67349204034
SN - 0014-5793
VL - 583
SP - 2067
EP - 2070
JO - FEBS Letters
JF - FEBS Letters
IS - 12
ER -